How to Treat Early Stage Non-Small Cell Lung Cancer in 2025

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain are joined by Dr. Deepa Rangachari, a thoracic medical oncologist and fellowship program director at Beth Israel Deaconess Medical Center. Together, they dived deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with a focus on curative intent. Key topics discussed include: •⁠  ⁠The importance of staging and lymph node evaluation in treatment planning. •⁠  ⁠The role of neoadjuvant chemoimmunotherapy and the impact of recent trial data, including the CHECKMATE 816 trial. •⁠  ⁠The significance of actionable mutations and the use of targeted therapies like Osimertinib and Alectinib. •⁠  ⁠The evolving role of ctDNA in treatment decisions and monitoring. •⁠  ⁠Insights into the management of side effects associated with Osimertinib and Alectinib. •⁠  ⁠The standard of care for unresectable stage 3 NSCLC, including concurrent chemoradiation and the use of Durvalumab. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us for an informative discussion that highlights the latest advancements in lung cancer treatment and the importance of personalized care. Don't forget to check out our other episodes in the lung cancer treatment algorithm series!